By a News Reporter-Staff News Editor at Disease Prevention Daily-- A new study on Drugs and Therapies- Kinase Inhibitors is now available. Financial supporters for this research include Taiju Life ...

At the recent American Society of Hematology annual meeting, researchers presented real-world outcomes for patients with ...

Within the 48-week treatment window, the Bruton’s tyrosine kinase (BTK) inhibitor triggered a 57.1% improvement in patients’ ...

Sanofi SA reported more hitches in the development of Bruton’s tyrosine kinase inhibitor tolebrutinib, saying the phase III Perseus study failed to meet its primary endpoint in primary progressive ...

Tukysa, a tyrosine kinase inhibitor by Pfizer, delays disease progression in HER2-positive metastatic breast cancer. In a late-stage trial with 654 patients, it improved progression-free survival by 8 ...

Insilico Medicine has developed a new class of small molecule inhibitors targeting diacylglycerol kinase alpha (DGKα) designed to restore T cell function and overcome resistance to immune checkpoint ...

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to ...

Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.Results suggest that nuclear GSK-3β ...

Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall ...

The global phosphoinositide 3-kinase inhibitor market is poised to witness significant growth, projected to expand at a robust CAGR of 5.61% during the forecast period from 2019 to 2026.